These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36902656)

  • 41. Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies.
    Shen NN; Zhang C; Wang N; Wang JL; Gu ZC; Han H
    Front Pharmacol; 2021; 12():645479. PubMed ID: 33815125
    [No Abstract]   [Full Text] [Related]  

  • 42. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis.
    Liu X; Huang M; Ye C; Xiao X; Yan C
    Clin Cardiol; 2021 Apr; 44(4):472-480. PubMed ID: 33682184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
    Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
    Marston XL; Wang R; Yeh YC; Zimmermann L; Ye X; Gao X; Brüggenjürgen B; Unverdorben M
    Int J Cardiol; 2022 Jan; 346():93-99. PubMed ID: 34780886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
    Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
    Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies.
    Sang C; Chen J; Sun J; Lai Y; Liu X; Zhu W
    Eur J Clin Invest; 2022 Oct; 52(10):e13819. PubMed ID: 35643840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.
    Patti G; Pecen L; Casalnuovo G; Manu MC; Kirchhof P; De Caterina R
    Clin Res Cardiol; 2023 Nov; 112(11):1517-1528. PubMed ID: 35976428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
    De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
    Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel anticoagulants in an older and frail population with atrial fibrillation: the effect of inappropriate dosing on clinical outcomes.
    de Almeida JPHCL; Martinho AS; Girão A; Barreiro I; Milner J; Ferreira MJV; Carvalho A; Baptista RT; Gonçalves L
    Eur Geriatr Med; 2020 Oct; 11(5):813-820. PubMed ID: 32557249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.
    Wetmore JB; Weinhandl ED; Yan H; Reyes JL; Herzog CA; Roetker NS
    Am J Kidney Dis; 2022 Nov; 80(5):569-579.e1. PubMed ID: 35469965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
    Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
    Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
    SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.
    Yamashita T; Koretsune Y; Nagao T; Shiosakai K
    J Arrhythm; 2020 Jun; 36(3):395-405. PubMed ID: 32528563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain.
    Díez-Villanueva P; Cosín-Sales J; Roldán-Schilling V; Barrios V; Riba-Artés D; Gavín-Sebastián O;
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.